Highlights

  • Shares in Renalytix fell 24.11% to 4.25p following the H1 FY26 update.
  • H1 revenue came in at USD 1.6m, with full-year guidance of USD 4m, up 33% YoY.
  • Market reaction reflected delays and complexities in EMR integrations tied to revenue ramp-up.

Renalytix PLC (LSE:RENX) saw its share price fall sharply in early trading on 11 February, down 24.11% to 4.25p at 10:35 am, as investors reacted to the company’s trading update for the six months ended 31 December 2025 (H1 FY26). The decline comes amid indications of slower-than-anticipated revenue growth and timing challenges with major healthcare system integrations, overshadowing longer-term prospects for the company’s kidneyintelX.dkd diagnostic platform.

Shares Slide Sharply After Trading News

Renalytix’s stock drop marked one of the most significant single-session declines in recent weeks The movement reflects investor concern over the timing of expected revenue acceleration and execution of electronic medical record (EMR) integrations, which underpin future sales growth.

Revenue Guidance Versus Execution Timing

Renalytix reiterated its FY26 revenue projection of USD 4m, representing a 33% increase compared with the previous year. However, management noted that the first half revenue ramp-up was slower than expected due to extended lead times and the complexity of integrating with larger healthcare provider EMR systems.

Investors appeared to interpret this as execution risk, with the near-term share price reflecting uncertainty about when revenue acceleration from new integrations will materialise. The company confirmed that three new EMR integrations completed in H1 FY26, and three more are expected to be onboarded in the current quarter — a factor that may support share price stability if realised.

Balancing Operational Progress and Market Sentiment

Renalytix outlined progress such as a planned pilot with a large hospital group involving an initial 1,000 patients and the potential to reach more than 40,000 chronic kidney disease patients. Separately, ongoing collaboration with Tempus AI on integrated testing and data collection was highlighted.

However, shorter-term stock performance remained dominated by investor focus on reported revenues and integration timelines rather than these strategic developments.

Renalytix’s share performance on 11 February, with a decline of more than 24%, illustrates how market sentiment can be sharply influenced by operational timing and revenue delivery expectations. Although full-year guidance was maintained and long-term initiatives continue, the stock’s movement underscores investor emphasis on execution clarity and near-term traction as drivers of valuation in the diagnostics sector.

Frequently Asked Questions (F&Q)

  1. Why did Renalytix shares fall today?
    Shares fell sharply in reaction to the H1 FY26 trading update, where slower-than-expected revenue ramp-up and execution timing for EMR integrations drew investor concern.
  2. What revenue guidance did Renalytix confirm?
    The company reaffirmed full-year FY26 revenue guidance of approximately USD 4m, representing about 33% year-on-year growth.
  3. What could support future share price recovery?
    Completion of planned EMR integrations, acceleration of testing adoption among large healthcare systems and progress in clinical validation studies may improve sentiment and longer-term valuations.